What is XLO's current stock price?

XLO (Xilio Therapeutics, Inc.) is currently trading at $8.25 with a market cap of $49.4M.

What sector is Xilio Therapeutics, Inc. in?

Xilio Therapeutics, Inc. (XLO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is XLO a good stock to buy?

Analysts have a Buy consensus on XLO with a price target of $98.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

XLO Xilio Therapeutics, Inc.

Healthcare

$8.25-3.79%ClosedMarket Cap: $49.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

18.59

P/S

0.92

EV/EBITDA

2.31

DCF Value

$34.66

FCF Yield

-116.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

70.7%

Operating Margin

-79.0%

Net Margin

-58.5%

ROE

-117.2%

ROA

-19.1%

ROIC

-34.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$12.6M	$-9.5M	$—
Q4 null	$13.7M	$10.4M	$—
FY null	$43.8M	$-35.0M	$—
Q3 null	$19.1M	$-16.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$98.00

Target (Median)

$98.00

Target Range

$98.00 - $98.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Blanchard Cheryl Rdirector

SellThu Apr 16

Blanchard Cheryl R

SellThu Apr 16

Shannon James Samueldirector

BuyMon Mar 30

GILEAD SCIENCES, INC.10 percent owner

BuyTue Feb 17

Luptakova Katarinaofficer: CHIEF MEDICAL OFFICER

SellMon Jan 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.13

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Peers

KZR